Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations

Completed · Not applicable

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if it is safe and effective to give adefovir plus other anti-HIV drugs to HIV-infected patients who have failed other anti-HIV drug combinations. This study will try to make adefovir available to all AIDS patients who need it. Some patients do not respond to anti-HIV drug combinations, even when different combinations are tried. Adefovir may be able to help these patients fight HIV.

Key facts

Study ID

NCT00002398

Run by

Gilead Sciences

Last updated by the study team

2005-06-24

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• You may be eligible for this study if you:
• Are HIV-positive.
• Have a CD4 cell count of 50 cells/mm3 or less within the past 2 months.
• Have a viral load (level of HIV in the body) of 30,000 copies/ml or more within the past 2 months.
• Are at least 13 years old (need consent of parent or guardian if under 18).
• Have failed to respond to an anti-HIV drug combination that included at least 2 nucleoside reverse transcriptase inhibitors and at least 1 protease inhibitor (PI).
• Do not have any other anti-HIV treatment options left.
• Agree to use effective methods of birth control during the study.

You may not qualify if…

• You will not be eligible for this study if you:
• Have certain serious medical conditions that would prevent you from completing the study, including serious kidney disorders.
• Have taken certain medications, including certain treatments for opportunistic (HIV-related) diseases.
• Are pregnant or breast-feeding.

Where it is running

• Gilead Sciences Inc — Foster City, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.